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Purpose: Matrix metalloproteinases (MMPs) have been 
implicated in the pathogenesis of pulmonary fibrosis. To under-
stand the role of MMP-2 and MMP-9 in pulmonary fibrosis, 
we evaluated the sequential dynamic change and different 
cellular sources of the 2 MMPs along the time course and their 
differential expression in the bronchoalveolar lavage (BAL) 
fluid and in the lung parenchyma of the bleomycin-induced 
pulmonary fibrosis models in rats. Materials and Methods: The 
level of MMPs in BAL fluid of 54 bleomycin-treated rats was 
assessed by zymography from 1 to 28 days after intratracheal 
bleomycin instillation. The level of MMPs in lung parenchyma 
was evaluated by immunohistochemistry. Results: MMP-2 and 
MMP-9 were markedly increased in both the BAL fluid and 
in the lung parenchyma of the bleomycin-treated rats, especially 
in the early phase with the peak on the 4th day. The levels 
of both MMPs in the BAL fluid correlated generally well to 
those in lung parenchyma, although the level of MMP-9 in 
BAL fluid was higher than MMP-2. In the lung parenchyma, 
the 2 MMPs, in early stage, were predominantly expressed in 
the inflammatory cells. In late stage, type II pneumocytes and 
alveolar epithelial cells at the periphery of the fibrotic foci 
retained MMP expression, which was more prominent in the 
cells showing features of cellular injury and/or repair. 
Conclusion:  In bleomycin-induced pulmonary fibrosis, MMP-2 
and MMP-9 may play important roles, especially in the early 
phase. In the late stage, the MMP-2 and MMP-9 may play a 
role in the process of repair.
Key Words: Pulmonary fibrosis, bleomycin, matrix metallo-
proteinase, matrix-metalloproteinase-2, matrix metalloprote-
inase-9
INTRODUCTION
Idiopathic pulmonary fibrosis is a cryptic, chronic 
disease, resulting in a progressive and severe pul-
monary insufficiency, however, the pathogenesis 
of idiopathic pulmonary fibrosis is not completely 
elucidated to date. Its main features include 
epithelial injury, fibroblastic proliferation, inflam-
mation, and increased matrix production.
1 The 
ultimate feature is the progressive fibrosis, resulting 
from dysregulated extracellular matrix control, 
where matrix metalloproteinase(MMP)s are believed 
to play important roles. Matrix metalloproteinase 
(MMP) is a group of Zn-dependent proteinases 
activated by proteolytic removal of their amino 
terminal, and their actions are inhibited by specific 
inhibitors, tissue inhibitors of matrix metallopro-
teinases (TIMP).
2 MMP-2 and MMP-9 are designated 
as 72-kDa gelatinase A and 92-kDa gelatinase B, 
respectively, and well known by their ability of 
degrading collagen type IV, the major constituent 
of the basement membrane. Studies showed that 
the activity of MMP-2 and MMP-9 is upregulated 
in many pulmonary diseases including pulmonary 
fibrosis,
3-7 and they are secreted by many different 
kinds of cells in the lungs.
8-11 But, the studies 
dealing with human lung can provide only a snap 
shot at a certain time point in its long course of 
disease. Thus, many studies so far rely mostly upon 
in vitro experiments or animal models among 
which bleomycin-induced pulmonary fibrosis is 
considered to be the most common and acceptable 
model.
12 However, even in bleomycin-induced 
pulmonary fibrosis, most studies about MMPs 
have been dealing with only 1 or 2 cell types or 
focused only on targeting certain mediators at a MMP-2 and MMP-9 in Pulmonary Fibrosis 69
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certain time point. Since the idiopathic pulmonary 
fibrosis is a long-term dynamic and progressive 
disease, the investigation of changing levels of the 
MMPs and their changing cellular sources along 
the time course may have significance in under-
standing the real pathophysiology of the condi-
tion. In this study, we tried to investigate the 
changes in the level of MMP-2 and MMP-9 and 
their various cellular sources in different stages of 
pulmonary fibrosis by estimating the changes of 
the activity of those MMPs at different time inter-
vals in bleomycin-induced pulmonary fibrosis in 
rats. 
MATERIALS AND METHODS
Animal model and experimental groups
Eighty one Sprague-Dawley male rats with body 
weight of around 200gm were divided into control 
group (n = 27) and bleomycin-administered experi-
mental group (n = 54). Six rats from experimental 
group and 3 from the control group were sacri-
ficed at 1, 2, 3, 4, 5, 7, 14, 21, and 28 days after 
bleomycin instillation.
Bleomycin administration
After rats were positioned prone under ether 
anesthesia, 1.5 unit/kg bleomycin (Nippon Kayaku 
Co., Tokyo, Japan) dissolved in saline was in-




After rats were sacrificed by arterial exsangui-
nations, lungs were dissected, and the left bronchus 
was ligated at its proximal part. Bronchoalveolar 
lavage was done only from the right lung. In 
detail, 3 mL of PBS was administered through a 
three way tube at 25 cm H2O pressure by gravity, 
remained in lung for 3 minutes, and withdrawn 
again by gravity. This process was repeated 5 
times. Collected lavage fluid was palced in 50 mL 
tube packed in ice. Two thirds of lavage fluid was 
prepared for cell count, and the remainder was 
kept in - 80°C to measure the activity of MMP-2 
and MMP-9 by zymography.
Cell count in BAL fluid
After centrifugation at 4°C and 1,500 rpm for 10 
minutes, the supernatant was discarded. After re-
moving the supernatant, the sediment was rinsed 
twice with RPMI 1,640. Cells were counted using 
hemocytometer. Total cell count was expressed as 
the number of cells per mL of BAL fluid. After 
adjusting the total cell number to 1.0 × 10
6/mL, 
200 μL of the sample was taken, centrifuged, 
smeared on a glass slide, air dried, and stained 
with Wright-Giemsa. Differential count was done 
by counting 500 cells on a high power view (× 
400) light microscopic field using ocular lens with 
a grid.
Microscopic examination
For microscopic examination, the left lungs from 
the rats were fixed in 10 % formalin for 8 hours, 
processed as usual, and embedded in paraffin. 
Three  μm serial section was stained with hema-
toxylin-eosin. Masson's trichrome stain was done 
to evaluate the degree of collagenous fibrosis.
Immunohistochemical examination
Three μm sections were prepared with formalin- 
fixed, paraffin-embedded tissue, deparaffinized, 
and rehydrated by serial alcohol treatment. 
Endogenous peroxidase quenching was done by 3 
% H2O2 treatment for 15 minutes. After rinsing 
with distilled water (D.W.) for 3 minutes, the 
sections were microwaved for 10 minutes in 10 
mM sodium citrate buffer (pH 6.0) for antigen 
retrieval. Then, the sections were incubated with 
mouse monoclonal MMP-2 (CA-4001), or mouse 
monoclonal MMP-9 (IIA5) (Neomarkers, Fremont, 
CA, USA) (dilution 1 : 50) for 1 hour at room tem-
perature (RT), and then, overnight at 4°C. The 
sections were reacted with Biotin labeled secon-
dary antibody and streptavidin HRP for 15 minutes 
each using LSAB II Rat kit (Dako Co., Carpinteria, 
CA, USA). After rinsing with PBS buffer, the sec-
tions were reacted with aminoethyl carbazole (AEC) 
and counterstained with Mayer's hematoxylin. 
The expression of the antibodies was semiquantita-Ji Young Kim, et al. 70
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Fig. 1. Total cell count in the BAL fluid of bleomycin- 
treated group was significantly higher than in the control
group (p < 0.05). Total cell count increased rapidly from 
the first day after bleomycin instillation, reaching the 
peak level on the 4th day. Then, it continuously decreased
till the 28th day. Exp: bleomycin-treated experimental 
group: n = 54, Control: control group: n = 27, Average 
cell count from each group was used.
tively evaluated through Allred score,
13 modified 
as follows; Grade 0, 1, 2, and 3 were determined 
according to the numbers of the positive cells (0 
= < 50 positive cells; 1 = 50 - 100 positive cells; 2 =
101 - 200 positive cells; 3 => 200 positive cells), 
and the intensity was evaluated as 1, 2, and 3 (1
= weakly positive; 2 = moderately positive; 3 = 
strongly positive). Immunohistochemical score 
was obtained by multiplying these two indices. 
All these examinations were done on 5 different 
high power fields (400 ×).
Gelatin zymography
The zymography of MMP-2 and MMP-9 from 
the BAL fluid was performed according to 
Laemmli method.
14 In detail, 4X non-reducing 
sample buffer [0.5 M Tris-HCL, 10% (w/v) sodium 
dodecyl sulfate (SDS) 4 mL, 0.1% bromophenol 
blue 0.5 mL, glycerol 2.0 mL, and add distilled 
water to a total volume of 10 mL] was added to 
the same volume of sample, incubated for 10 
minutes at RT, and then injected to the wells in 
a precast 10% (w/v) acrylamide gel (Novex, San 
Diego, CA, USA) containing 0.1% gelatin. Electro-
phoresis was performed at 4°C and 20 mA (125 V) 
for 3 hours. After electrophoresis, the gels were 
washed twice with 2.5% (v/v) triton X-100 rena-
turing buffer, rinsed with water, incubated over-
night at 37°C in the developing buffer (50 mM 
Tris-based, 200mM NaCl, 5 mM CaCl2, pH 7.6, 
0.02% Brij). The gels were stained with 0.5% (w/v) 
Coomassie brilliant blue and destained in a solu-
tion of 25% ethanol 10% acetic acid, and then 
examined for the bright appearing bands where 
the gelatin was degraded and disappeared. To 
assess the gelatinolytic activity of the MMPs, the 
width and optical density of the bands were 
analyzed by the computer-assisted image analyzer 
(Bioprofile, Vilber Lourmat Biotechnology, Marne 
La Vallee, Cedex, France). The relative values of 
the bands were calculated using the HT-1080 cell 
lines as standards.
Statistical analysis
Statistical analysis was done with Wilcoxon Rank 
Sum Test using SAS program.
RESULTS
Analysis of bronchoalveolar lavage fluid
Total cell count of BAL fluid
Total cell count of BAL fluid was significantly 
higher in the bleomycin-treated experimental group 
compared to those of the control group. Total cell 
count of the experimental group increased by 1.5 
to 3 times from the first day. It reached its peak 
on the 4th day and decreased slowly thereafter. 
Total cell count on the 28th day was nearly the 
same in the two groups (Fig. 1).
Differential count of BAL fluid
In contrast to the control group, in which more 
than 95% of the total cells in BAL fluid were 
mononuclear cells, the neutrophil count in the 
experimental group increased from the first day, 
reaching its peak (52.1%) on the 4th day, and de-
creased dramatically until the 14th day, reaching 
to a level of 3.7% on the 28th day (Fig. 2). Eosino-
phils were temporarily increased from the 4th day 
to 7th day, and decreased thereafter. Lymphocyte 
count increased until the 3rd day and remained 
at a constant level.MMP-2 and MMP-9 in Pulmonary Fibrosis 71
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Fig. 2. The percentage of neutrophil in the BAL fluid in 
the bleomycin-treated group was significantly higher 
than in the control group (p < 0.05). The percentage of 
neutrophil was markedly increased from the first day 
after bleomycin instillation, reaching the peak level on 
the 4th day, and then decreased rapidly thereafter. Exp: 
bleomycin-treated experimental group: n = 54, Control: 
control group: n = 27. Average value from each group 
was used.
Fig. 3. Histological findings of bleomycin-treated group. (A) 3rd day. Swollen cuboidal epithelial cells of the terminal 
bronchiole and type II pneumocytes (arrows) and inflammatory cell infiltration in the peribronchiolar and perivascular area 
(arrowhead). (B) 5th day. A number of small tubular structures of bronchiolar epithelial cells, "bronchiolization" foci (arrow) 
are seen around the terminal bronchiole. (C) 14th day. Some foci of small intraalveolar fibrosis are seen (arrows). (D) 28th 
day. Dense mature collagen stained deep blue in Masson-trichrome stain is widening the alveolar septae and destroying 
the normal alveolar pattern (A, B, and C: H&E; D: Masson's trichrome, A and C: × 100; B, and D: × 40).
Light microscopic features 
Hematoxylin-eosin stain findings
In saline-treated control group, the inflamma-
tory reaction was only mild throughout the whole 
experimental period, except focal mild lympho-
cytic infiltration around the small vessels. Fibrosis 
was scarce. On the other hand, in the bleomycin- 
treated experimental group, prominent inflamma-
tory reaction was noted from the first day, showing 
some inflammatory infiltrate around the small 
vessels and interstitium along with mild intersti-
tial edema. Inflammatory infiltration began around 
the small vessels and terminal bronchioles, and 
gradually spread to adjacent parenchyma, forming 
scattered foci of discrete inflammatory aggregate 
throughout the pulmonary parenchyma. A few 
neutrophils, lymphocytes, and macrophages were 
present in the edematous alveolar spaces, and 
these intraalveolar inflammatory foci were conti-
nuous to the inflammatory infiltrates around the 
small vessels and terminal bronchioles. On the Ji Young Kim, et al. 72
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third and the 4th day, intraalveolar edema became 
prominent. More lymphocytes and macrophages 
were present in the alveolar spaces and, from the 
7th day, they infiltrated in the alveolar septa and 
expanded them. This septal inflammatory infiltrate 
was specifically prominent on the 14th day. The 
bronchiolar epithelial cells were swollen showing 
vacuolar changes. Another characteristic feature 
was the so-called "bronchiolization",
15 the ingrowth 
of cuboidal cells from adjacent bronchioles to 
alveoli, forming a tubular structure, which was 
most apparent from the 4th to 7th days. Around 
the foci of bronchiolization, type II pneumocytes 
showed features such as swelling, cytoplasmic 
vacuolization, or nuclear enlargement, suggesting 
damage and/or activation. These changes of the 
type II pneumocytes were most prominent during 
the 3rd to 7th day and lasted thereafter, especially 
near the fibrotic foci. In addition, a layer of flat 
epithelial cells was often found to surround the 
fibrotic foci and appeared to be connected to the 
activated type II pneumocytes. In regard to fibrosis, 
immature-appearing collagen fibers, which were 
stained reddish purple on Masson trichrome stain, 
began to deposit focally on the 7th day at around 
the arterioles, bronchioles, and alveolar septae 
where inflammatory changes were present. On the 
14th day, the area of collagen accumulation became 
widened, and intraalveolar fibrosis became 
apparent. On the 28th day, multiple fibrotic foci 
with mature collagen which was stained deep 
blue on Masson trichrome were noted at the al-
veolar septae, distorting the normal parenchymal 
architecture (Fig. 3). 
Immunohistochemical stain findings
In saline-instilled control groups, MMP-2 and 
MMP-9 were expressed in moderate degrees in 
the bronchiolar epithelial cells and smooth muscle 
cells in the arteriolar wall, and weakly expressed 
in a few alveolar macrophages and type II pneu-
mocytes as well as in some lymphocytes around 
the arterioles and bronchioles. In the experimental 
groups, however, the bronchiolar epithelial cells 
showed intense immunoreactivity throughout the 
entire course. The cells showing features of cellular 
injury, activation and/or repair particularly showed 
more prominent expression of both MMPs. The 
inflammatory cells were also strongly positive. 
MMP-9 was almost exclusively stained in the 
neutrophils, whereas MMP-2 was expressed more 
strongly in the macrophages. Small numbers of 
mast cells were also positive to the MMPs. The 
MMPs were also expressed in the intraalveolar 
edema fluid which was most prominent on the 
3rd and the 4th days. Atypical type II pneumo-
cytes started to stain strongly for MMP-2 and 
MMP-9 from the 3rd day, most intensely on the 4th 
day. From the 7th day, there were fewer inflam-
matory cells, and the intensity of the MMP-2 and 
MMP-9 staining was weakened. On the 14th day, 
positive reaction of the macrophages and atypical 
type II pneumocytes was retained at the periphery 
of the fibrotic foci, and the single-layered attenu-
ated alveolar epithelial cells surrounding the 
fibrotic foci were also positive to both MMPs (Fig. 
4). The overall expression of MMP-2 and MMP-9 
along the time sequence dynamically changed 
according to the immunohistochemical score. The 
expression was dramatically increased from the 
1st day, reaching the peak on the 4th day. From 
the 5th day, they were slightly diminished, but 
still remained at significantly higher levels till the 
14th day, compared to the control groups (p < 0.05). 
Although there was no statistically significant dif-
ference in the expression between the MMP-2 and 
MMP-9, MMP-2 appeared to be expressed at a 
higher level on the 4th day, compared to MMP-9 
and also showed a tendency to decline less rapidly 
(Fig. 5).
Gelatin zymographic analysis
Zymographic analysis of the BAL fluid showed 
distinct bands of gelatinolytic activity at 72-kDa 
and 92-kDa, which correspond to MMP-2 and 
MMP-9, respectively. The gelatinolytic activity in-
creased from the first day, reaching the maximum 
level on the 4th day (Fig. 6). The change of MMP- 
9 was more profound, reaching 6 times the level on 
the 4th day compared to that of the 1st day, and 
then rapidly decreased and remained unchanged 
at 2 times the level from the 5th to 14th day. 
Finally, it started to decrease again on the 21st day 
(Fig. 7B). The change of MMP-2 was not as pro-
found as MMP-9, nevertheless, still showed a 
similar pattern, reaching the maximum on the 4th MMP-2 and MMP-9 in Pulmonary Fibrosis 73
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Fig. 4. The immunohistochemical expression of the MMP-2 and MMP-9 in bleomycin-treated group (A, C, and E: MMP-2; 
B, D, and F: MMP-9). (A and B) On the 4th day, the bronchiolar epithelial cells that are swollen and activated show prominent
MMP positivity (arrows). MMPs are also strongly expressed in the inflammatory cells in the surrounding parenchyma. 
(C and D) On the 7th day, the MMP-2 and MMP-9 are expressed in the foci of bronchiolization (arrows). Some inflam-
matory cells, such as neutrophils and macrophages, still show expression (arrowheads). (E and F) On 14th day, the expres-
sion of MMP-2 (E) and MMP-9 (F) is decreased in most part, but still retained at the periphery of the fibrotic foci (arrows).
day and decreasing thereafter. Interestingly, the 
MMP-2 stayed in a relatively higher level than 
MMP-9 on the 14th and 21st day (Fig. 7A). On the 
14th day, a small amount of active form of MMP-2 
(62 kDa) was also observed (Fig. 6).
DISCUSSION
In normal condition, the homeostasis of the ex-
tracellular matrix of the lung is maintained and 
tightly controlled. In idiopathic pulmonary fibrosis, 
however, this homeostasis is severely disrupted 
and accumulation of ECM continues, resulting in 
progressive fibrosis. The pathogenesis of IPF is 
not yet completely understood. Inflammation after 
epithelial injury is believed to be the integral part 
of the pathophysiology of pulmonary fibrosis,
16 
especially in early phase, although the links between 
fibrosis and inflammation have been debated.
17-19 
Dysregulated wound repair is also believed to be 
important pathogenetic mechanisms.
18,19 Key 
players, such as TGF-beta 1, TNF, and IL-1 beta 
have been reported to be crucial in sustaining in-
flammation and promoting progressive fibrosis. 
10,20,21 MMPs and their inhibitors, TIMPs, have 
been known to play important roles in pulmonary 
fibrosis through their function in matrix protein 
degradation and its control.
3-5 Among many types 
of MMPs, MMP-2 and MMP-9 have been known Ji Young Kim, et al. 74
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Fig. 5. The change in the levels of MMP-2 and MMP-9 
in the lung parenchyma of bleomycin-treated group, 
shown by immunohistochemistry. The immunohistoche-
mical score was evaluated semiquantitatively as des-
cribed in methods. Both MMP-2 and MMP-9 rapidly 
increased from the first day to the 4th day, and decreased
thereafter till the 28th day.
Fig. 6. Gelatin zymography of MMP-2 (72 kDa) and MMP-9
(92 kDa) in the BAL fluid of the bleomycin-treated group.
The representative gelatin zymography sample shows 
that the band of MMP-9 is strong, particularly on the 4th 
days. It gets weaker from the 14th to 21st days. On the 
14th day, weak band of active MMP-2 (62kDa) is noted. 
4, 14, and 21: experimental g r o u p ;  C :  c o n t r o l  g r o u p .
Fig. 7. The change of the gelatinolytic activity of MMP-2 
and MMP-9 in the BAL fluid of the bleomycin-treated 
group. The activity of MMP-2 (A) and MMP-9 (B) is rapidly
increased and reaches the peak level on the 4th day and 
then decreases thereafter. The change of the MMP-9 is 
more pronounced than that of the MMP-2. The MMP-2 
declined less rapidly.
to be important and to show increased activity in 
many pulmonary diseases including pulmonary 
fibrosis.
4,5,22,23 Herein, we demonstrated that the 
activity of MMP-2 and MMP-9 in the broncho-
alveolar lavage fluid and lung parenchyma 
increased rapidly in the early phase, reaching the 
peak levels on the 4th day, and then consistently 
decreased thereafter. This is in accordance with 
the previous studies,
24,25 which showed that the 
activity of the MMP-2 and MMP-9 increases in the 
early stage and decreases thereafter. However, the 
timing of the peak level in previous studies is 
somewhat different, and this may be due to the 
difference of experimental animals used or to the 
different time schedules when animals were 
sacrificed. The changes of the MMPs in the BAL 
fluid correlated to the total/differential cell counts 
in the BAL fluid. The level of the 2 MMPs in the 
lung parenchyma was not significantly different 
from each other, however, the change of the 
gelatinolytic activity of the MMP-9 in the BAL 
fluid was more prominent than that of MMP-2. 
This is maybe due to that in early phase, the 
MMP-9 was expressed strongly in neutrophils 
which more frequently existed in the intraalveolar 
spaces rather than in the lung parenchyma per se. 
There was a temporal change in the major 
sources of the MMPs. In early phase until the 4th 
A
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day, both two MMPs were mainly expressed in 
the inflammatory cells. However, more specifi-
cally, MMP-2 was noted more frequently in alveolar 
macrophages, whereas MMP-9 in neutrophils. 
Since previous studies showed that these MMPs 
were co-localized with the type IV collagen in the 
basement membrane,
3 the MMP-2 and MMP-9 in 
this early phase secreted by macrophages and 
neutrophils may play an important role in de-
grading the basement membrane, thereby facili-
tating the inflammatory cell migration. In mid- 
phase (the 5th to 7th day), parenchymal cells, such 
as bronchiolar epithelial cells and type II pneumo-
cytes, in addition to the inflammatory cells, also 
comprise important cellular sources expressing 
these MMPs. Especially, those with the features of 
cellular injury, such as cellular swelling, vacuoli-
zation, and nuclear atypia, expressed MMP-2 and 
MMP-9 more prominently. The bronchiolization 
foci
15 observed frequently from the 4th to 7th day 
also showed prominent MMP-2 and MMP-9 
reactivity. In later phase (from 14th to 28th days), 
the main cellular sources of the MMPs were again 
the type II pneumocytes, however, mainly the 
ones surrounding the fibrotic foci. After the 14th 
day when fibrosis progressed, the overall expres-
sion of the MMP-2 and MMP-9 was very low. The 
fibroblasts, immature or mature collagen fibers at 
the center of the fibrotic foci, didn’t show much 
MMP expression, while a few alveolar macrophages 
and type 2 pneumocytes retained the expression 
of the MMPs at the periphery of the fibrotic foci, 
presumably the advancing front of the fibrosis.
Bronchiolization, frequently observed from 4th 
to 7th day, is regarded as a reparative reaction to 
cellular injury to the alveolar epithelial cells.
15,26 
Also, cells surrounding the fibrotic foci are known 
to be derived from regenerating pneumocytes.
27 
The fact that the MMP-2 and MMP-9 were ex-
pressed in the cells with features of cellular injury/ 
repair may suggest the roles of MMP-2 and 
MMP-9 in cellular regeneration. The roles of MMPs 
in relation with cellular regeneration in pulmo-
n a r y  f i b r o s i s  h a s  a l s o  b e e n  s u g g e s t e d  b y  s e v e r a l  
previous studies,
28-30 implicating their role in 
facilitating the migration of epithelial cells to the 
injured site.
Proinflammatory cytokines such as TNF-alpha 
and IL-6, which were increased in the early phase 
of pulmonary fibrosis and are essential in pro-
gression of early pulmonary inflammation to 
pulmonary fibrosis
31,32 have been associated with 
increased MMP levels
33 or induction of MMP pro-
duction from various cell types including alveolar 
epithelial cells, alveolar fibroblasts, and alveolar 
macrophages.
34-36 They were also shown to induce 
other cytokines such as TGF-beta 1.
32 These proin-
flammatory cytokines may play roles in pulmo-
nary fibrosis by recruiting inflammatory cells and 
inducing MMPs production from recruited cells, 
thus facilitating the migration of those inflamma-
tory cells and further promoting fibrosis through 
a synergistic action with profibrotic cytokine TGF- 
beta 1. TGF-beta 1, the most potent fibrogenic cyto-
kine, has been reported to increase in pulmonary 
fibrosis and to be expressed in alveolar epithelial 
cells in higher levels even in later phase of 
pulmonary fibrosis.
37,38 It was also reported that 
TGF-beta 1 induces transition of alveolar epithelial 
cells to mesenchymal/fibroblasts-like cells and 
MMP-2 expression in those cells,
39 possibly sug-
gesting that MMP-2 production in alveolar epithe-
lial cells by TGF-beta 1 may promote pulmonary 
fibrosis. However, the mechanisms of cytokines 
and MMPs need to be further elucidated, since 
many other cytokines such as IL-10
40 and IL-8
41  are 
also involved, and there are conflicting results, 
too.
42
In our study, the levels of the MMP-2 and MMP- 
9 in the lung parenchyma corresponded well to 
those of BAL fluid. The antibodies used for 
immunohistochemistry could equally stain both 
latent and active forms without any preference, 
therefore, active forms of both MMPs were to be 
evaluated by the zymography. It was expected 
that the active forms of MMP-2 and MMP-9 might 
have been increased in the early phase of pulmo-
nary fibrosis when the total MMP-2 and MMP-9 
activity reached the maximum. However, the 
zymography of the BAL revealed no active forms 
of the MMPs from the 4th to 7th day when the 
MMP levels were the highest. Only a small 
amount of active MMP-2 was detected on the 14th 
day, and the active form of MMP-9 was not noted 
throughout the entire time course. It is quite 
possible that the active forms of MMPs were more 
likely present in the lung parenchyma where 
active protein degradation occurs and that the Ji Young Kim, et al. 76
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level of the active MMPs in the BAL fluid might 
be too low to be detected, or might have been 
degraded too quickly after their normal function. 
There are some studies reporting that the levels of 
active MMP did not necessarily correlate to total 
MMP levels.
10,11,43 The fact that active form of only 
MMP-2, but not MMP-9, was detected in later 
phase of fibrosis is in accordance with an another 
study which showed similar result, suggesting 
different roles of MMP-2 and MMP-9 along in the 
time course.
25 Presumably, MMP-9 is more impor-
tant in early phase when active degradation of the 
basement membrane and inflammatory cell migra-
tion occur, whereas MMP-2 may play roles in later 
phase in regard to the formation of the fibrotic 
foci and cellular repair.
In this study, we didn’t investigate the activity 
of TIMPs. Considering the fact that MMP activity 
is regulated by TIMPs, the role of MMPs in pulmo-
nary fibrosis has to be understood in association 
with that of TIMPs. The activities of TIMP-1 or 
TIMP-2
3,44-46 were reported to increase in pulmo-
nary fibrosis, especially in the acute phase of 
pulmonary fibrosis or acute lung injury model. It 
has also been suggested that TIMP is related to 
the process of bronchial epithelial cell regenera-
tion.
30 More detailed information on the functions 
of MMP in relation with TIMPs in pulmonary 
fibrosis needs to be clarified.
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